TanL, WangQ, ZhangD, et al.: Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther, 2020; 5:1–3.
2.
IngrahamNE, Lotfi-EmranS, ThielenBK, et al.: Immunomodulation in COVID-19. Lancet Respir Med, 2020; S2213-2600(20)30226-5.
3.
CSIR fights COVID-19. https://urdip.res.in/covid19/vertical3.jsp. (Last accessed on May8, 2020).
4.
MehtaP, McAuleyDF, BrownM, et al.: COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020; 395:1033–1034.
5.
ChaudhryH, ZhouJ, ZhongY, et al.: Role of cytokines as a double-edged sword in sepsis. In Vivo (Brooklyn), 2013; 27:669–684.
6.
GuptaS, SinghS, ChouhanK: Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts. Indian J Dermatol Venereol Leprol, 2014; 80:509.
7.
SharmaP, KarHK, KaurH, et al.: Induction of lepromin positivity and immunoprophylaxis in household contacts of multibacillary leprosy patients: a pilot study with a candidate vaccine, Mycobacterium w. Int J Lepr Other Mycobact Dis, 2000; 68:136–142.
8.
SharmaSK, KatochK, SarinR, et al.: Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial. Sci Rep, 2017; 7:3354.
9.
SinghIG, MukherjeeR, TalwarGP, et al.: In vitro characterization of T cells from Mycobacterium w-vaccinated mice. Infect Immun, 1992; 60:257–263.
10.
SharmaP, KarHK, MisraRS, et al.: Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antileprosy vaccine. Int J Lepr Other Mycobact Dis, 1999; 67:259–269.
